These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 3607879)

  • 1. Tumors secreting human TNF/cachectin induce cachexia in mice.
    Oliff A; Defeo-Jones D; Boyer M; Martinez D; Kiefer D; Vuocolo G; Wolfe A; Socher SH
    Cell; 1987 Aug; 50(4):555-63. PubMed ID: 3607879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia.
    Tracey KJ; Morgello S; Koplin B; Fahey TJ; Fox J; Aledo A; Manogue KR; Cerami A
    J Clin Invest; 1990 Dec; 86(6):2014-24. PubMed ID: 2254457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat.
    Stovroff MC; Fraker DL; Swedenborg JA; Norton JA
    Cancer Res; 1988 Aug; 48(16):4567-72. PubMed ID: 3165053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice.
    Qin Z; van Tits LJ; Buurman WA; Blankenstein T
    Blood; 1995 May; 85(10):2779-85. PubMed ID: 7742538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of animal models for head and neck cancer cachexia.
    Cannon T; Couch M; Yin X; Guttridge D; Lai V; Shores C
    Laryngoscope; 2007 Dec; 117(12):2152-8. PubMed ID: 17921906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cachectin: a hormone that triggers acute shock and chronic cachexia.
    Tracey KJ; Lowry SF; Cerami A
    J Infect Dis; 1988 Mar; 157(3):413-20. PubMed ID: 3278061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism and treatment of cancer cachexia in tumor-bearing mice].
    Li T; Li C
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):188-91. PubMed ID: 10920893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells.
    Matthys P; Dijkmans R; Proost P; Van Damme J; Heremans H; Sobis H; Billiau A
    Int J Cancer; 1991 Aug; 49(1):77-82. PubMed ID: 1908442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic responses to cachectin/TNF. A brief review.
    Tracey KJ; Cerami A
    Ann N Y Acad Sci; 1990; 587():325-31. PubMed ID: 2193578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NF-kappaB and cytokine in experimental cancer cachexia.
    Zhou W; Jiang ZW; Tian J; Jiang J; Li N; Li JS
    World J Gastroenterol; 2003 Jul; 9(7):1567-70. PubMed ID: 12854165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor (cachectin) mediates induction of cachexia by cord factor from mycobacteria.
    Silva CL; Faccioli LH
    Infect Immun; 1988 Dec; 56(12):3067-71. PubMed ID: 3053451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins.
    Fong Y; Moldawer LL; Marano M; Wei H; Barber A; Manogue K; Tracey KJ; Kuo G; Fischman DA; Cerami A
    Am J Physiol; 1989 Mar; 256(3 Pt 2):R659-65. PubMed ID: 2784290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.
    Tracey KJ; Wei H; Manogue KR; Fong Y; Hesse DG; Nguyen HT; Kuo GC; Beutler B; Cotran RS; Cerami A
    J Exp Med; 1988 Mar; 167(3):1211-27. PubMed ID: 3351436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cachectin activity in the serum of cachectic, tumor-bearing rats.
    Stovroff MC; Fraker DL; Norton JA
    Arch Surg; 1989 Jan; 124(1):94-9. PubMed ID: 2910253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.
    Teng MN; Park BH; Koeppen HK; Tracey KJ; Fendly BM; Schreiber H
    Proc Natl Acad Sci U S A; 1991 May; 88(9):3535-9. PubMed ID: 2023898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha.
    Bassukas ID; Hofmockel G; Maurer-Schultze B
    Anticancer Res; 1994; 14(1A):237-45. PubMed ID: 8166454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological responses to cachectin.
    Tracey KJ; Lowry SF; Cerami A
    Ciba Found Symp; 1987; 131():88-108. PubMed ID: 2836140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein.
    Teng MN; Turksen K; Jacobs CA; Fuchs E; Schreiber H
    Clin Immunol Immunopathol; 1993 Nov; 69(2):215-22. PubMed ID: 8403559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.
    Cahlin C; Körner A; Axelsson H; Wang W; Lundholm K; Svanberg E
    Cancer Res; 2000 Oct; 60(19):5488-93. PubMed ID: 11034092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia.
    Langstein HN; Doherty GM; Fraker DL; Buresh CM; Norton JA
    Cancer Res; 1991 May; 51(9):2302-6. PubMed ID: 1901758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.